- Home
- AGIO vs SONO Comparison
AGIO vs SONO Comparison
Compare AGIO & SONO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- SONO
- Stock Information
- Founded
- AGIO 2007
- SONO 2002
- Country
- AGIO United States
- SONO United States
- Employees
- AGIO N/A
- SONO N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- SONO Consumer Electronics/Video Chains
- Sector
- AGIO Health Care
- SONO Consumer Discretionary
- Exchange
- AGIO Nasdaq
- SONO Nasdaq
- Market Cap
- AGIO 2.4B
- SONO 2.0B
- IPO Year
- AGIO 2013
- SONO 2018
- Fundamental
- Price
- AGIO $40.16
- SONO $16.37
- Analyst Decision
- AGIO Strong Buy
- SONO Strong Buy
- Analyst Count
- AGIO 4
- SONO 3
- Target Price
- AGIO $59.33
- SONO $17.00
- AVG Volume (30 Days)
- AGIO 567.8K
- SONO 1.4M
- Earning Date
- AGIO 10-30-2025
- SONO 11-05-2025
- Dividend Yield
- AGIO N/A
- SONO N/A
- EPS Growth
- AGIO N/A
- SONO N/A
- EPS
- AGIO N/A
- SONO N/A
- Revenue
- AGIO $44,791,000.00
- SONO $1,443,276,000.00
- Revenue This Year
- AGIO $25.57
- SONO $2.89
- Revenue Next Year
- AGIO $153.24
- SONO $8.55
- P/E Ratio
- AGIO N/A
- SONO N/A
- Revenue Growth
- AGIO 36.26
- SONO N/A
- 52 Week Low
- AGIO $23.42
- SONO $7.63
- 52 Week High
- AGIO $62.58
- SONO $18.06
- Technical
- Relative Strength Index (RSI)
- AGIO 45.66
- SONO 47.25
- Support Level
- AGIO $38.90
- SONO $15.88
- Resistance Level
- AGIO $44.10
- SONO $17.89
- Average True Range (ATR)
- AGIO 1.72
- SONO 0.69
- MACD
- AGIO -0.44
- SONO -0.16
- Stochastic Oscillator
- AGIO 24.58
- SONO 22.39
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.